<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796558</url>
  </required_header>
  <id_info>
    <org_study_id>532021</org_study_id>
    <nct_id>NCT04796558</nct_id>
  </id_info>
  <brief_title>Validation of Arterio Venous Access Stage (AVAS) Classification</brief_title>
  <acronym>VAVASC</acronym>
  <official_title>Validation of Arterio Venous Access Stage Classification by Using Machine Learning in Prediction of Vascular Access Creation and Uninterrupted Use of the Vascular Access for Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular surgery, University hospital Královské Vinohrady, Prague</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vascular surgery, University hospital Královské Vinohrady, Prague</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VAVASC trial is an observational multicentre study. The aim of this trial is to validate AVAS&#xD;
      (arteriovenous vascular access stage) classification. The classification is used for&#xD;
      determining which type of access is the most suitable for the patient on the basis of the&#xD;
      patient´s vascular anatomy&#xD;
&#xD;
      The methodology of this trial is to apply AVAS classification on patients who are indicated&#xD;
      for creation of vascular access for hemodialysis. Data on these patients (vascular anatomy&#xD;
      status, AVAS type, and predicted type of arterio venous access, demographic data etc.) will&#xD;
      be than statistically analysed. Patients will then undergo creation of the selected&#xD;
      arteriovenous access. They will be observed in terms of the access functionality. The follow&#xD;
      up will be 1 to 3 years. The second aim of this study is to evaluate the relationship between&#xD;
      AVAS classification and uninterrupted use of the created arterio venous access.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasound of upper limb vessels as a part of preoperative assessment of patients referred&#xD;
      for arteriovenous access placement has been recommended repeatedly in several studies and&#xD;
      guidelines. Each patient needing arterio-venous access (AVA) is unique and has different&#xD;
      possibilities for fistula creation that depend on many factors as well the anatomical&#xD;
      condition of inflow arteries and outflow veins, the so-called 'arteriovenous access map'. In&#xD;
      2020 we created, published and retrospectively evaluated the inter-rater reliability of the&#xD;
      AVAS classification, which is a simplified way of sharing the information about suitability&#xD;
      for access creation depending on vascular anatomy (doi: 10.1093/ckj/sfaa189).&#xD;
&#xD;
      However, before routine use of the AVAS classification system in clinical practise it&#xD;
      requires prospective validation and comparison with other clinical factors. Finally, whether&#xD;
      the AVAS classification can be used for the prediction of vascular access function as defined&#xD;
      by uninterrupted use of vascular access for dialysis without need for any access&#xD;
      intervention/procedures (SONG-HD, doi: 10.1053/j.ajkd.2017.12.003) remains to be tested.&#xD;
&#xD;
      This project has two main parts:&#xD;
&#xD;
        1. Validation of AVAS classification with and without combination with other factors using&#xD;
           a predictive statistical model&#xD;
&#xD;
           .&#xD;
&#xD;
        2. Validation of AVAS classification in terms of prediction of uninterrupted use of&#xD;
           successfully created vascular access for dialysis.&#xD;
&#xD;
      The data will be collected prospectively. Both parts of the project will be taking place&#xD;
      simultaneously.&#xD;
&#xD;
      Data will be collected prospectively (Belfast City Hospital, UK, University hospital&#xD;
      Královské Vinohrady Prague CZ). Other centres around the world will be asked for cooperation&#xD;
      (announcement will be posted via Twitter, ResearchGate, LinkedIn, Facebook and Kidney&#xD;
      Academy) in January 2021. The data collected will be the parameters of the vessels on the&#xD;
      upper limb, in order to be able to evaluate AVAS (VAVASC FORM). Along with anatomical&#xD;
      dispositions of the patients, other parameters will be collected.&#xD;
&#xD;
      Obligatory parameters (parameters A):&#xD;
&#xD;
      Side of the arm (Left / Right) Dominant hand (Left / Right) Allen's test (Positive /&#xD;
      Negative) (A negative Allen's test is demonstration of a complete palmar arch and intact&#xD;
      collateral blood flow to the hand) Sex(M / F) Age, Height, Weight, BMI, Diabetes (Yes / No)&#xD;
      Central venous line previous or current (Yes / No) Side of the central venous line if place&#xD;
      (Left / Right)&#xD;
&#xD;
      Non-obligatory parameters (parameters B):&#xD;
&#xD;
      Smoking history (Yes / No) Hypertension (Yes / No) Heart failure (Yes / No) Ischemic heart&#xD;
      disease (Yes / No) Cancer (previous or current) (Yes / No)&#xD;
&#xD;
      In order to evaluate uninterrupted use of the vascular access for dialysis (part 2 of the&#xD;
      study), we will follow the patients and do a time to event analysis of the arteriovenous&#xD;
      accesses for one year after creation or up until the first intervention for maintaining&#xD;
      patency has been performed. If the patient dies during follow up the date of death should be&#xD;
      recorded. The data for this part will be collected prospectively (Belfast City Hospital, UK,&#xD;
      University hospital Královské Vinohrady Prague, CZ and other centres).&#xD;
&#xD;
      Predictive models will be used for validation of AVAS classification. The data will be&#xD;
      registered via electronic database and analysed by Waldauf, P. and O'Neill, S.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Arterio Venous Access Stage (AVAS) evaluation</measure>
    <time_frame>Baseline - recruiting (Year 1) - physical examination, data collection and evaluation of Arterio Venous Access Stage (AVAS)</time_frame>
    <description>What type of the Arterio Venous Access Stage (AVAS classification) the patient has based on his/her vascular anatomy of upper limbs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterio Venous Access type predicted</measure>
    <time_frame>Baseline - recruiting (Year 1) - physical examination, data collection and evaluation of Arterio Venous Access Stage (AVAS) and predicting a type of arterio venous access</time_frame>
    <description>What type of the Arterio Venous Access is predicted based on AVAS and other clinical factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final Arterio Venous Access</measure>
    <time_frame>Follow up (up to 1-2 years) what type of arterio venous access was eventually created</time_frame>
    <description>What type of the arterio venous access was eventually created (in corelation with AVAS evaluation and the predicted arteriovenous access type)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functionality of the arterio venous access</measure>
    <time_frame>Year 2-3 - follow up, collection the data about the functionality (uninterrupted use) of the arterio venous access and evaluation of the relation between AVAS and the functionality of the arterio venous access</time_frame>
    <description>Uninterrupted use of the created arterio venous access</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Arteriovenous Graft</condition>
  <condition>Arteriovenous Fistula</condition>
  <condition>Dialysis Access Malfunction</condition>
  <condition>Kidney Failure</condition>
  <condition>Dialysis Related Complication</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AVAS Classification</intervention_name>
    <description>Validation of AVAS classification</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - patients with kidney insufficiency who are indicated for creation of arterio venouss&#xD;
        access for dialysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients indicated for creation of arterio venous access for dialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients who disagree to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vascular surgery, University hospital Královské Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kateřina Lawrie, MD</last_name>
      <phone>+420728137996</phone>
      <email>katerina.lawrie@fnkv.cz</email>
    </contact>
    <contact_backup>
      <last_name>Peter Baláž, MD</last_name>
      <email>balaz.peter.pb@hmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <link>
    <url>https://www.vavasc.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>May 9, 2021</last_update_submitted>
  <last_update_submitted_qc>May 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arterio venous access</keyword>
  <keyword>Dialysis</keyword>
  <keyword>AVAS</keyword>
  <keyword>Predictive modelling</keyword>
  <keyword>Machine learning</keyword>
  <keyword>VAVASC</keyword>
  <keyword>Multicentre</keyword>
  <keyword>Observational</keyword>
  <keyword>Prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT04796558/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

